Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CACNA2D3 antisense RNA 1 (CACNA2D3-AS1) is a long non-coding RNA (lncRNA) transcribed from the opposite DNA strand relative to the CACNA2D3 gene. LncRNAs such as CACNA2D3-AS1 do not encode proteins but can regulate gene expression at the transcriptional and post-transcriptional levels, often through antisense interactions with their sense counterpart genes[4]. Antisense RNAs are increasingly recognized as important regulators of gene expression, but as of now, there is limited published information specifically about the biological role or disease associations of CACNA2D3-AS1. There are currently no known drugs, biomarker roles, or therapeutic interventions directly targeting CACNA2D3-AS1[5]. This molecule is classified as a regulatory non-coding RNA rather than a traditional therapeutic target such as an enzyme, receptor, or channel. It is not a protein-coding gene and is not considered a canonical therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CACNA2D3 antisense RNA 1 (CACNA2D3-AS1).